UNSPSC 51162504: Ammonium chloride/ipecac

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51162504 Ammonium chloride/ipecac is a Commodity code that in recent state and local procurement activity covers naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesale channels to government health and community facilities. State and local health departments, counties, and cooperative purchasing alliances are the primary issuing bodies, with solicitations targeting manufacturers and authorized distributors capable of meeting cGMP and Drug Supply Chain Security Act compliance requirements, maintaining relationships with established pharmaceutical wholesalers, and delivering products on quarterly or standing-order schedules to multiple locations across participating jurisdictions.

Recent activity spans Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP procurement requires vendors to work through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (weighted at 75 percent), cGMP certification, and compliance with federal pharmaceutical supply chain security standards.